Genetic Therapy Gets NIH Patent
GAITHERSBURG, Md--The National Institutes of Health (NIH) has licensed its broad patent covering gene therapy techniques to Genetic Therapy, Inc. The inventors cited on the patent are gene therapy pioneers W. French Anderson, Steven Rosenberg, and Michael Blaese.
GAITHERSBURG, Md--The National Institutes of Health (NIH) haslicensed its broad patent covering gene therapy techniques toGenetic Therapy, Inc. The inventors cited on the patent are genetherapy pioneers W. French Anderson, Steven Rosenberg, and MichaelBlaese.
In other news, Genetic Therapy has announced the start of a multicenterphase I/II clinical trial using gene therapy to treat inoperablemalignant brain tumors. This trial is being conducted in parallelwith an ongoing trial for operable malignant brain tumors.
The initial study will enroll 15 patients who will receive injectionsinto the tumor that produce genetically altered vectors. Thesevectors transfer into the tumor cells the gene for the enzymethymidine kinase. Cells that express this gene produce thymidinekinase, making them susceptible to ganciclovir (Cytovene). Gancicloviris then given to destroy tumor cells that have expressed the enzyme.
FDA Announces Probe Into bluebird's Elivaldogene Autotemcel for Hematologic Malignancies
November 27th 2024Approved as Skysona, the therapy has been reported to be related to cases of hematologic malignancies, including life-threatening instances of myelodysplastic syndrome and acute myeloid leukemia.
